WuXi AppTec Co. Ltd - Asset Resilience Ratio
WuXi AppTec Co. Ltd (WX8) has an Asset Resilience Ratio of 3.51% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read WX8 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how WuXi AppTec Co. Ltd's Asset Resilience Ratio has changed over time. See WX8 net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down WuXi AppTec Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of WuXi AppTec Co. Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €2.94 Billion | 3.51% |
| Total Liquid Assets | €2.94 Billion | 3.51% |
Asset Resilience Insights
- Limited Liquidity: WuXi AppTec Co. Ltd maintains only 3.51% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
WuXi AppTec Co. Ltd Industry Peers by Asset Resilience Ratio
Compare WuXi AppTec Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 6.56% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Imagion Biosystems Ltd
AU:IBX |
Diagnostics & Research | 150.16% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for WuXi AppTec Co. Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for WuXi AppTec Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.54% | €1.23 Billion ≈ $1.44 Billion |
€80.33 Billion ≈ $93.91 Billion |
+1.52pp |
| 2023-12-31 | 0.01% | €11.00 Million ≈ $12.86 Million |
€73.67 Billion ≈ $86.13 Billion |
+0.01pp |
| 2022-12-31 | 0.00% | €2.00 Million ≈ $2.34 Million |
€64.69 Billion ≈ $75.63 Billion |
-0.95pp |
| 2021-12-31 | 0.96% | €527.29 Million ≈ $616.46 Million |
€55.13 Billion ≈ $64.45 Billion |
-9.02pp |
| 2020-12-31 | 9.98% | €4.62 Billion ≈ $5.40 Billion |
€46.29 Billion ≈ $54.12 Billion |
+4.16pp |
| 2019-12-31 | 5.82% | €1.70 Billion ≈ $1.99 Billion |
€29.24 Billion ≈ $34.18 Billion |
-3.56pp |
| 2018-12-31 | 9.38% | €2.13 Billion ≈ $2.48 Billion |
€22.67 Billion ≈ $26.50 Billion |
+9.26pp |
| 2017-12-31 | 0.12% | €14.74 Million ≈ $17.23 Million |
€12.58 Billion ≈ $14.71 Billion |
-3.98pp |
| 2016-12-31 | 4.10% | €434.19 Million ≈ $507.61 Million |
€10.59 Billion ≈ $12.38 Billion |
-- |
About WuXi AppTec Co. Ltd
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manuf… Read more